DOCSLIB.ORG

Table 4. Complete Initial Laboratory Testing Resultsa

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Table 4. Complete Initial Laboratory Testing Resultsa Table 4. Complete initial laboratory testing resultsa Marker Value Reference range Malabsorption and dysbiosis markers Malabsorption markers Indoleacetic acid 2.0 ≤ 4.2 Phenylacetic acid 0.32 ≤ 0.12 Bacterial dysbiosis markers Dihydroxyphenylpropionic acid 6.1 ≤ 5.3 3-hydroxyphenylacetic acid 3.4 ≤ 8.1 4-hydroxyphenylacetic acid 17 ≤ 29 Benzoic acid 0.06 ≤ 0.05 Hippuric acid 611 ≤ 603 Yeast/fungal dysbiosis markers Arabinose 158 ≤ 96 Citramalic acid 3.9 ≤ 5.8 Tartaric acid 66 ≤ 15 Cellular energy and mitochondrial metabolites Carbohydrate metabolism Lactic acid 4.9 1.9-19.8 Pyruvic acid 27 7-32 β-OH-butyric acid 2.0 ≤ 2.8 Energy metabolism Citric acid 113 40-520 Cis-aconitic acid 12 10-36 Isocitric acid 44 22-65 α-ketoglutaric acid 13 4-52 Succinic acid < dl 0.4-4.6 Malic acid 1.6 ≤ 3.0 β-OH-β-methylglutaric acid 12 ≤ 15 Fatty acid metabolism Adipic acid 3.9 ≤ 2.8 Suberic acid 1.3 ≤ 2.1 Creatinine concentration Creatinine 3.6 3.1-19.5 µmol/L Neurotransmitter metabolites Vanilmandelic acid 2.7 0.4-3.6 Homovanillic acid 3.4 1.2-5.3 5-OH-indoleacetic acid 18.5 3.8-12.1 3-methyl-4-OH-phenylglycol 0.11 0.02-0.22 Kynurenic acid < dl ≤ 7.1 Quinolinic acid 7.0 ≤ 9.1 Kynurenic/quinolinic ratio NR ≥ 0.44 Vitamin markers α-ketoadipic acid 0.6 ≤ 1.7 α-ketoisovaleric acid 0.81 ≤ 0.97 α-ketoisocaproic acid 0.59 ≤ 0.89 α-keto-β-methylvaleric acid 1.0 ≤ 2.1 Formiminoglutamic acid 0.7 ≤ 1.5 Glutaric acid 0.22 ≤ 0.51 Isovalerylcys 2.5 ≤ 3.7 Methylmalonic acid 0.8 ≤ 1.9 Xanthurenic acid < dl ≤ 0.96 3-hydroxypropionic acid 9 5-22 3-hydroxyisovaleric acid 7 ≤ 29 Toxin and detoxification markers α-Ketophenylacetic acid (from Styrene) 0.43 ≤ 0.46 α-Hydroxyisobutyric acid (from methyl 5.1 ≤ 6.7 tertiary-butyl ether) Orotic acid 0.66 0.33-1.01 Pyroglutamic acid 48 16-34 Tyrosine metabolism Homogentisic acid 9 ≤ 19 2-hydroxyphenylacetic acid 0.53 ≤ 0.76 Nutritionally essential amino acids Arginine 24 10-64 Histidine 242 271-993 Isoleucine 38 24-58 Leucine 47 30-87 Lysine 39 45-286 Methionine 68 30-82 Phenylalanine 35 26-71 Taurine 169 68-538 Threonine 122 65-252 Tryptophan 88 28-111 Valine 26 23-61 Nonessential protein amino acids Alanine 136 146-486 Asparagine 63 49-182 Aspartic acid 60 35-86 Cysteine 82 21-78 Cystine 39 26-78 γ-aminobutyric acid 13 ≤ 31 Glutamic acid 17 5-21 Glutamine 143 172-570 Proline 4 2-18 Tyrosine 31 33-124 Intermediary metabolites B vitamin markers α-aminoadipic acid < dl 11-73 α-amino-N-butyric acid 19 9-49 β-aminoisobutyric acid 95 22-192 Cystathionine 4 6-33 3-methylhistidine 234 131-318 Urea cycle markers Ammonia 19.5 14.0-19.0 µmol/g creatinine Citrulline 38 12-45 Ornithine 20 4-21 Urea 326 168-465 µmol/g creatinine Glycine/serine metabolites Glycine 341 639-3306 Serine 214 187-568 Ethanolamine 71 208-514 Phosphoethanolamine 31 18-70 Phosphoserine 39 28-63 Sarcosine 53 ≤ 48 Dietary peptide-related markers Anserine (dipeptide) 11 7-126 Carnosine (dipeptide) 18 10-104 1-methylhistidine 1265 92-1046 β-alanine 16 ≤ 21 Markers for urine representativeness Glutamine/glutamate 8 ≥ 10 Ammonia 19.5 14.0-49.0 µmol/g creatinine Arginine/ornithine 1.2 ≥ 1.1 Urine representativeness index 8 5-10 Omega 3 fatty acids α-Linolenic 18:3 0.10 ≥ 0.09 wt % Eicosapentaenoic (EPA) 20:5 0.32 ≥ 0.16 wt % Docosapentaenoic 22:5 1.95 ≥ 1.14 wt % Docosahexaenoic 22:6 2.6 ≥ 2.1 wt % Omega 3, % 5.0 ≥ 3.8 Omega 6 fatty acids Linoleic 18:2 8.4 10.5-16.9 wt % γ-Linolenic 18:3 0.09 0.03-0.13 wt % Dihomo-γ-linolenic (DGLA) 20:3 1.72 ≥ 1.19 wt % Arachidonic (AA) 20:4 22 15-21 wt % Docosatetraenoic 22:4 3.26 1.50-4.20 wt % Eicosapentaenoic 20:2 0.29 ≤ 0.26 wt % Omega 6, % 35.6 30.5-39.7 Omega 9 fatty acids Oleic 18:1 10 10-13 wt % Nervonic 24:1 2.8 2.1-3.5 wt % Omega 9, % 13.3 13.3-16.6 Saturated fatty acids Palmitic C16:0 21 18-23 wt % Stearic C18:0 19 14-17 wt % Arachidic C20:0 0.23 0.22-0.35 wt % Behenic C22:0 0.81 0.92-1.68 wt % Tricosanoic C23:0 0.18 0.12-0.18 wt % Lignoceric C24:0 1.7 2.1-3.8 wt % Pentadecanoic C15:0 0.14 0.07-0.15 wt % Margaric C17:0 0.33 0.22-0.37 wt % Saturated fats, % 43.9 39.8-43.6 Monounsaturated fats Omega 7 fats Palmitoleic 16:1 0.43 ≤ 0.64 wt % Vaccenic 18:1 1.18 ≤ 1.13 wt % Trans fat Elaidic 18:1 0.59 ≤ 0.59 wt % Delta-6 desaturase activity Linoleic/DGLA 18:2/20:3 4.9 6.0-12.3 Cardiovascular risk Omega 6s/omega 3s 7.1 3.4-10.7 AA/EPA 20:4/20:5 69 12-125 Omega 3 index 3.0 ≥ 4.0 Oxidative stress markers Glutathione (whole blood) 486 ≥ 669 µmol/L Lipid peroxides (urine) 6.6 ≤ 10.0 µmol/g creatinine 8-OHdG (urine) 18 ≤ 15 µg/g creatinine Coenzyme Q10, ubiquinone (plasma) 0.20 0.43-1.49 µg/mL Elemental markers (RBCs) Nutrient elements Copper 0.591 0.466-0.721 µg/g Magnesium 45.6 30.1-56.5 µg/g Manganese 0.013 0.007-0.038 µg/g Potassium 2837 2220-3626 µg/g Selenium 0.39 0.25-0.76 µg/g Zinc 10.6 7.8-13.1 µg/g Toxic elements Lead 0.012 ≤ 0.048 µg/g Mercury < dl ≤ 0.0039 µg/g Antimony 0.001 ≤ 0.002 µg/g Arsenic 0.029 ≤ 0.071 µg/g Cadmium 0.001 ≤ 0.001 µg/g Tin < dl ≤ 0.0009 µg/g a All biomarkers reported in µmol/g creatinine unless otherwise noted. dl = detection limit; nr = not recorded; wt % = weighted percentage. .
Load more

Recommended publications
  • Cloning, Biochemical Characterization and Inhibition of Alanine Racemase from Streptococcus Iniae
    bioRxiv preprint doi: https://doi.org/10.1101/611251; this version posted April 16, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Cloning, Biochemical Characterization and Inhibition of Alanine racemase from Streptococcus iniae Murtala Muhammad, Yangyang Li, Siyu Gong, Yanmin Shi, Jiansong Ju, Baohua Zhao*, Dong Liu* College of Life Science, Hebei Normal University, Shijiazhuang 050024, China; *Correspondence: Baohua Zhao and Dong Liu; E-mail: [email protected], [email protected]; College of Life Science, Hebei Normal University, Shijiazhuang 050024, China. Running Title: Inhibitors of alanine racemase Summary statement: Antimicrobial target 1 bioRxiv preprint doi: https://doi.org/10.1101/611251; this version posted April 16, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. ABSTRACT Streptococcus iniae is a pathogenic and zoonotic bacteria that impacted high mortality to many fish species, as well as capable of causing serious disease to humans. Alanine racemase (Alr, EC 5.1.1.1) is a pyridoxal-5′-phosphate (PLP)-containing homodimeric enzyme that catalyzes the racemization of L-alanine and D-alanine. In this study, we purified alanine racemase from the pathogenic strain of S. iniae, determined its biochemical characteristics and inhibitors. The alr gene has an open reading frame (ORF) of 1107 bp, encoding a protein of 369 amino acids, which has a molecular mass of 40 kDa. The optimal enzyme activity occurred at 35°C and a pH of 9.5.
    [Show full text]
  • The Clinical Significance of the Organic Acids Test
    The Clinical Significance of the Organic Acids Test The Organic Acids Test (OAT) provides an accurate metabolic snapshot of what is going on in the body. Besides offering the most complete and accurate evaluation of intestinal yeast and bacteria, it also provides information on important neurotransmitters, nutritional markers, glutathione status, oxalate metabolism, and much more. The test includes 76 urinary metabolite markers that can be very useful for discovering underlying causes of chronic illness. Patients and physicians report that treating yeast and bacterial abnormalities reduces fatigue, increases alertness and energy, improves sleep, normalizes bowel function, and reduces hyperactivity and abdominal pain. The OAT Assists in Evaluating: ■ Krebs Cycle Abnormalities ■ Neurotransmitter Levels ■ Nutritional Deficiencies ■ Antioxidant Deficiencies ■ Yeast and Clostridia Overgrowth ■ Fatty Acid Metabolism ■ Oxalate Levels ■ And More! The OAT Pairs Well with the Following Tests: ■ GPL-TOX: Toxic Non-Metal Chemical Profile ■ IgG Food Allergy + Candida ■ MycoTOX Profile ■ Phospholipase A2 Activity Test Learn how to better integrate the OAT into your practice, along with our other top tests by attending one of our GPL Academy Practitioner Workshops! Visit www.GPLWorkshops.com for workshop dates and locations. The following pages list the 76 metabolite markers of the Organic Acids Test. Included is the name of the metabolic marker, its clinical significance, and usual initial treatment. INTESTINAL MICROBIAL OVERGROWTH Yeast and Fungal Markers Elevated citramalic acid is produced mainly by Saccharomyces species or Propionibacteria Citramalic Acid overgrowth. High-potency, multi-strain probiotics may help rebalance GI flora. A metabolite produced by Aspergillus and possibly other fungal species in the GI tract. 5-Hydroxy-methyl- Prescription or natural antifungals, along with high-potency, multi-strain probiotics, furoic Acid may reduce overgrowth levels.
    [Show full text]
  • Amino Acid Disorders
    471 Review Article on Inborn Errors of Metabolism Page 1 of 10 Amino acid disorders Ermal Aliu1, Shibani Kanungo2, Georgianne L. Arnold1 1Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 2Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI, USA Contributions: (I) Conception and design: S Kanungo, GL Arnold; (II) Administrative support: S Kanungo; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: E Aliu, GL Arnold; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Georgianne L. Arnold, MD. UPMC Children’s Hospital of Pittsburgh, 4401 Penn Avenue, Suite 1200, Pittsburgh, PA 15224, USA. Email: [email protected]. Abstract: Amino acids serve as key building blocks and as an energy source for cell repair, survival, regeneration and growth. Each amino acid has an amino group, a carboxylic acid, and a unique carbon structure. Human utilize 21 different amino acids; most of these can be synthesized endogenously, but 9 are “essential” in that they must be ingested in the diet. In addition to their role as building blocks of protein, amino acids are key energy source (ketogenic, glucogenic or both), are building blocks of Kreb’s (aka TCA) cycle intermediates and other metabolites, and recycled as needed. A metabolic defect in the metabolism of tyrosine (homogentisic acid oxidase deficiency) historically defined Archibald Garrod as key architect in linking biochemistry, genetics and medicine and creation of the term ‘Inborn Error of Metabolism’ (IEM). The key concept of a single gene defect leading to a single enzyme dysfunction, leading to “intoxication” with a precursor in the metabolic pathway was vital to linking genetics and metabolic disorders and developing screening and treatment approaches as described in other chapters in this issue.
    [Show full text]
  • Orfadin, INN-Nitisinone
    SCIENTIFIC DISCUSSION 1. Introduction 1.1 Problem statement Hereditary tyrosinaemia type 1 (HT-1) is a devastating inherited disease, mainly of childhood. It is characterised by severe liver dysfunction, impaired coagulation, painful neurological crises, renal tubular dysfunction and a considerable risk of hepatocellular carcinoma (Weinberg et al. 1976, Halvorsen 1990, Kvittingen 1991, van Spronsen et al. 1994, Mitchell et al. 1995). The condition is caused by an inborn error in the final step of the tyrosine degradation pathway (Lindblad et al. 1977). The incidence of HT-1 in Europe and North America is about one in 100,000 births, although in certain areas the incidence is considerably higher. In the province of Quebec, Canada, it is about one in 20,000 births (Mitchell et al. 1995). The mode of inheritance is autosomal recessive. The primary enzymatic defect in HT-1 is a reduced activity of fumarylacetoacetate hydrolase (FAH) in the liver, the last enzyme in the tyrosine degradation pathway. As a consequence, fumaylacetoacetate (FAA) and maleylacetoacetate (MAA), upstream of the enzymatic block, accumulate. Both intermediates are highly reactive and unstable and cannot be detected in the serum or urine of affected children. Degradation products of MAA and FAA are succinylacetone (SA) and succinylacetoacetate (SAA) which are (especially SA) toxic, and which are measurable in the serum and urine and are hallmarks of the disease. SA is also an inhibitor of Porphobilinogen synthase (PBG), leading to an accumulation of 5-aminolevulinate (5-ALA) which is thought to be responsible for the neurologic crises resembling the crises of the porphyrias. The accumulation of toxic metabolites starts at birth and the severity of phenotype is reflected in the age of onset of symptoms (Halvorsen 1990, van Spronsen et al.
    [Show full text]
  • Selection and Characterization of Alanine Racemase Inhibitors Against
    Wang et al. BMC Microbiology (2017) 17:122 DOI 10.1186/s12866-017-1010-x RESEARCHARTICLE Open Access Selection and characterization of alanine racemase inhibitors against Aeromonas hydrophila Yaping Wang1, Chao Yang2, Wen Xue1, Ting Zhang1, Xipei Liu1, Jiansong Ju1, Baohua Zhao1* and Dong Liu1* Abstract Background: Combining experimental and computational screening methods has been of keen interest in drug discovery. In the present study, we developed an efficient screening method that has been used to screen 2100 small-molecule compounds for alanine racemase Alr-2 inhibitors. Results: We identified ten novel non-substrate Alr-2 inhibitors, of which patulin, homogentisic acid, and hydroquinone were active against Aeromonas hydrophila. The compounds were found to be capable of inhibiting Alr-2 to different extents with 50% inhibitory concentrations (IC50) ranging from 6.6 to 17.7 μM. These compounds inhibited the growth of A. hydrophila with minimal inhibitory concentrations (MICs) ranging from 20 to 120 μg/ml. These compounds have no activity on horseradish peroxidase and D-amino acid oxidase at a concentration of 50 μM. The MTT assay revealed that homogentisic acid and hydroquinone have minimal cytotoxicity against mammalian cells. The kinetic studies indicated a competitive inhibition of homogentisic acid against Alr-2 with an inhibition constant (Ki) of 51.7 μM, while hydroquinone was a noncompetitive inhibitor with a Ki of 212 μM. Molecular docking studies suggested that homogentisic acid binds to the active site of racemase, while hydroquinone lies near the active center of alanine racemase. Conclusions: Our findings suggested that combining experimental and computational methods could be used for an efficient, large-scale screening of alanine racemase inhibitors against A.
    [Show full text]
  • COMPILATION of AMINO ACIDS, DRUGS, METABOLITES and OTHER COMPOUNDS in MASSTRAK AMINO ACID ANALYSIS SOLUTION Paula Hong, Kendon S
    COMPILATION OF AMINO ACIDS, DRUGS, METABOLITES AND OTHER COMPOUNDS IN MASSTRAK AMINO ACID ANALYSIS SOLUTION Paula Hong, Kendon S. Graham, Alexandre Paccou, T homas E. Wheat and Diane M. Diehl INTRODUCTION LC conditions Physiological amino acid analysis is commonly performed to LC System: Waters ACQUITY UPLC® System with TUV monitor and study a wide variety of metabolic processes. A wide Column: MassTrak AAA Column 2.1 x 150 mm, 1.7 µm variety of drugs, foods, and metabolic intermediates that may Column Temp: 43 ˚C be present in biological fluids can appear as peaks in amino Flow Rate: 400 µL/min. acid analysis, therefore, it is important to be able to identify Mobile Phase A: MassTrak AAA Eluent A Concentrate, unknown compounds.1,2,3 The reproducibility and robustness of diluted 1:10 the MassTrak Amino Acid Analysis Solution make this method well Mobile Phase B: MassTrak AAA Eluent B suited to such a study as well.4 Weak Needle Wash: 5/95 Acetonitrile/Water Strong Needle Wash: 95/5 Acetonitrile/Water Gradient: MassTrak AAA Standard Gradient (as provided in kit) Detection: UV @ 260 nm Injection Volume: 1 µL EXPERIMENTAL Injection Mode: Partial Loop with Needle Overfill (PLNO) Compound sample preparation A library of compounds was assembled. Each compound was derivatized individually and spiked into the MassTrak™ AAA Solution Standard prior to chromatographic analysis. The elution RESULTS AND DISCUSSION position of each tested compound could be related to known amino acids. A wide variety of antibiotics, pharmaceutical compounds and metabolite by-products are found in biological fluids. The reten- 1.
    [Show full text]
  • The Skin in Genetically-Controlled Metabolic Disorders P
    Review Article J Med Genet: first published as 10.1136/jmg.10.2.101 on 1 June 1973. Downloaded from Journal of Medical Genetics (1973). 10, 101. The Skin in Genetically-controlled Metabolic Disorders P. C. H. NEWBOLD Department of Medicine, Cambridge University Medical School, Hills Road, Cambridge CB2 2QL Diseased nature oftentimes breaks forth however, it may lead to difficulty in assessing intelli- In strange eruptions.-Henry IV, part 1, III, i. gence, which is within normal range in 50% of The skin is now commonly accepted as a mirror patients. There is suggestive evidence of a re- of internal disease, but as with other looking-glasses, lationship between subnormal folate levels and low the evidence offered may be selected or ignored. intelligence (Carey et al, 1968), and studies have The epidermis is an interesting structure, especially shown increased turnover of folate coenzymes and rich in tyrosine, phenylalanine, tryptophan, and resulting folate depletion in these patients (Carey et histidine, when compared with the corium (Roth- al, 1968; Butterworth, Krumdieck, and Baugh, man, 1965). Tyrosinaemia and histidinaemia do 1971). There is also a high incidence of an organic not include cutaneous manifestations, but culture of brain syndrome following intracranial vascular skin fibroblasts is a helpful diagnostic tool for study- thromboses (Dunn, Perry, and Dolman, 1966), ing metabolic defects such as citrullinaemia, cysti- copyright. nosis, and maple-syrup urine disease (Scriver, 1969). Most of the conditions now to be described are rare, but if these metabolic diseases were com- mon, there could be no human race as we know it. Homocystinuria http://jmg.bmj.com/ This most informative anomaly was discovered during a study of mentally retarded patients in Ire- land (Carson and Neill, 1962).
    [Show full text]
  • Biochemical Investigations in the Rare Disease Alkaptonuria: Studies on the Metabolome and the Nature of Ochronotic Pigment
    Biochemical Investigations in the Rare Disease Alkaptonuria: Studies on the Metabolome and the Nature of Ochronotic Pigment Thesis submitted in accordance with the requirements of the University of Liverpool for the degree of Doctor of Philosophy by Brendan Paul Norman September 2019 ACKNOWLEDGEMENTS It is hard to describe the journey this PhD has taken me on without reverting to well-worn clichés. There has been plenty of challenges along the way, but ultimately I can look back on the past four years with a great sense of pride, both in the work presented here and the skills I have developed. Equally important though are the relationships I have established. I have lots of people to thank for playing a part in this thesis. First, I would like to thank my supervisors, Jim Gallagher, Lakshminarayan Ranganath and Norman Roberts for giving me this fantastic opportunity. Your dedication to research into alkaptonuria (AKU) is inspiring and our discussions together have always been thoughtful and often offered fresh perspective on my work. It has been a pleasure to work under your supervision and your ongoing support and encouragement continues to drive me on. It has truly been a pleasure to be part of the AKU research group. Andrew Davison deserves a special mention - much of the highs and lows of our PhD projects have been experienced together. Learning LC-QTOF-MS was exciting (and continues to be) but equally daunting at the start of our projects (admittedly more so for me as a Psychology graduate turned mass spectrometrist!). I am very proud of what we have achieved together, largely starting from scratch on the instrument, and we are continuing to learn all the time.
    [Show full text]
  • Antioxidants Minerals B-Vitamins
    Patient: SAMPLE PATIENT DOB: Sex: MRN: Results Overview Supplementation Antioxidants for High Need Vitamin A / Carotenoids Vitamin C Vitamin E / Tocopherols α-Lipoic Acid CoQ10 B-Vitamins Thiamin - B1 Riboflavin - B2 Niacin - B3 Pyridoxine - B6 Biotin - B7 Folic Acid - B9 Folic Acid - B9 - Dose = 1,200 mcg Cobalamin - B12 Minerals Magnesium Manganese Molybdenum Zinc © Genova Diagnostics · A. L. Peace-Brewer, PhD, D(ABMLI), Lab Director · CLIA Lic. #34D0655571 · Medicare Lic. #34-8475 GDX-4-214 Patient: SAMPLE PATIENT ID: Page 2 SUGGESTED SUPPLEMENT SCHEDULE Daily Provider Recommended Supplements Patient's Daily Daily Intake (DRI) Recommendations Recommendations Antioxidants Vitamin A / Carotenoids 2,333 IU 5,000 IU Vitamin C 75 mg 250 mg Vitamin E / Tocopherols 22 IU 200 IU α-Lipoic Acid 100 mg CoQ10 60 mg B-Vitamins Thiamin - B1 1.1 mg 25 mg Riboflavin - B2 1.1 mg 25 mg Niacin - B3 14 mg 30 mg Pyridoxine - B6 1.3 mg 10 mg Biotin - B7 30 mcg 100 mcg Folic Acid - B9 400 mcg 1,200 mcg Cobalamin - B12 2.4 mcg 500 mcg Minerals Magnesium 320 mg 600 mg Manganese 1.8 mg 5 mg Molybdenum 45 mcg 75 mcg Zinc 8 mg 20 mg Essential Fatty Acids Omega-3 Oils 500 mg 500 mg Digestive Support Probiotics 25 billion CFU Pancreatic Enzymes 5,000 IU Other Vitamins Vitamin D 600 IU Amino Acid mg/day Amino Acid mg/day Arginine 0 Methionine 0 Asparagine 0 Phenylalanine 0 Cysteine 55 Serine 0 Glutamine 0 Taurine 0 Glycine 0 Threonine 0 Histidine 0 Tryptophan 0 Isoleucine 0 Tyrosine 0 Leucine 0 Valine 0 Lysine 0 Recommendations for age and gender-specific supplementation are set by The Suggested Supplemental Schedule is provided at the request of the comparing levels of nutrient functional need to optimal levels as described in ordering practitioner.
    [Show full text]
  • Analysis of Naturally Occurring Phenolic Compounds in Aromatic Plants by RP-HPLC Coupled to Diode Array Detector (DAD) and GC-MS After Silylation
    Foods 2013, 2, 90-99; doi:10.3390/foods2010090 OPEN ACCESS foods ISSN 2304-8158 www.mdpi.com/journal/foods Article Analysis of Naturally Occurring Phenolic Compounds in Aromatic Plants by RP-HPLC Coupled to Diode Array Detector (DAD) and GC-MS after Silylation Charalampos Proestos 1,†,* and Michael Komaitis 2,† 1 Laboratory of Food Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771, Athens, Greece 2 Laboratory of Food Chemistry and Analysis, Department of Food Science and Technology, Agricultural University of Athens, 11855, Athens, Greece; E-Mail: [email protected] † These authors contributed equally to this work. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +30-210-727-4160 (ext. 160); Fax: +30-210-727-4476. Received: 6 February 2013; in revised form: 4 March 2013 / Accepted: 5 March 2013 / Published: 13 March 2013 Abstract: The following aromatic plants of Greek origin, Origanum dictamnus (dictamus), Eucalyptus globulus (eucalyptus), Origanum vulgare L. (oregano), Mellisa officinalis L. (balm mint) and Sideritis cretica (mountain tea), were examined for the content of phenolic substances. Reversed phase HPLC coupled to diode array detector (DAD) was used for the analysis of the plant extracts. The gas chromatography-mass spectrometry method (GC-MS) was also used for identification of phenolic compounds after silylation. The most abundant phenolic acids were: gallic acid (1.5–2.6 mg/100 g dry sample), ferulic acid (0.34–6.9 mg/100 g dry sample) and caffeic acid (1.0–13.8 mg/100 g dry sample). (+)-Catechin and (−)-epicatechin were the main flavonoids identified in oregano and mountain tea.
    [Show full text]
  • Transfer of Expertise on Rare Metabolic Diseases in Adults
    ALKAPTONURIA Pathophysiology Signs and symptoms Old treatment Prognosis New treatment? Harold W de Valk, endocrinologist Zaira M. Barrientos, researcher University Medical Centre Utrecht The Netherlands Parts of the presentation Background of the disease • Biochemical pathophysiology • Pathology • Genetics Signs and symptoms Complications and prognosis The Dutch survey Current treatment New treatment • How to test effectivity, safety and toxicity in orphan drugs • What about NTBC? Research & Development; outcome analysis Conclusions Background of the disease Deficiency of the enzyme homogentisic acid oxidase Accumulation of homogentisic acid in blood, tissue and urine Rest activity can vary from person to person Biochemical pathway Phenylalanine Tyrosine Tyrosine amino transaminase Phenylalanine hydroxylase 4 Hydroxyphenylpyruvate 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) Homogentisic acid Deficiency in Homogentisate 1,2-dioxygenase Alkaptonuria Maleylacetoacetate Maleylacetoacetate Porphobilinogen isomerase Fumarylacetoacetate Deficiency in Hereditary Fumarylacetoacetase tyrosinaemia I Fumarate + Acetoacetate Tricyclic acid cycle Genetic defect Pathophysiologic pathway Pathogenesis Excess HGA Excess HGA Excess HGA in plasma in urine Polyphenol Polymers Binding to oxidase in tissue sulhydrylgroups BQA Binding to collagen Free radical damage Cartilage damage Joint disease Genetics Autosomal recessive disease Many DNA-mutations Detected hot spots: • a valley in Slovakia • Dominican republic − geographically and socially
    [Show full text]
  • Evaluation of Antioxiodant Drugs for the Treatment of Ochronotic Alkaptonuria in an in Vitro Human Cell Model
    ORIGINAL ARTICLE 84 JournalJournal ofof Cellular Evaluation of Antioxiodant Drugs Physiology for the Treatment of Ochronotic Alkaptonuria in An In Vitro Human Cell Model LAURA TINTI,1 ADRIANO SPREAFICO,1,2** DANIELA BRACONI,3 LIA MILLUCCI,3 GIULIA BERNARDINI,3 FEDERICO CHELLINI,1 GIOVANNI CAVALLO,2 ENRICO SELVI,1,2 MAURO GALEAZZI,2,3 ROBERTO MARCOLONGO,2 JAMES A. GALLAGHER,2,4 2,3 AND ANNALISA SANTUCCI * 1Sezione di Reumatologia, Dipartimento di Medicina Clinica e Scienze Immunologiche, Universita` degli Studi di Siena, Policlinico Le Scotte, Siena, Italy 2Centro Interdipartimentale per lo Studio Biochimico delle Patologie Osteoarticolari, Universita` degli Studi di Siena, Siena, Italy 3Dipartimento di Biologia Molecolare, Universita` degli Studi di Siena, Siena, Italy 4Department of Human Anatomy & Cell Biology, University of Liverpool, Liverpool, UK Alkaptonuria (AKU) is a rare autosomal recessive disease, associated with deficiency of homogentisate 1,2-dioxygenase activity in the liver. This leads to an accumulation of homogentisic acid (HGA) and its oxidized derivatives in polymerized form in connective tissues especially in joints. Currently, AKU lacks an appropriate therapy. Hence, we propose a new treatment for AKU using the antioxidant N- acetylcysteine (NAC) administered in combinations with ascorbic acid (ASC) since it has been proven that NAC counteracts the side- effects of ASC. We established an in vitro cell model using human articular primary chondrocytes challenged with an excess of HGA (0.33 mM). We used this experimental model to undertake pre-clinical testing of potential antioxidative therapies for AKU, evaluating apoptosis, viability, proliferation, and metabolism of chondrocytes exposed to HGA and treated with NAC and ASC administered alone or in combination addition of both.
    [Show full text]